Amphotericin B inhalation powder

Amphotericin B inhalation powder
Trade Name
Orphan Indication Prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies
USA Market Approval USA
USA Designation Date 2005-12-15 00:00:00
Sponsor Novartis Pharmaceuticals Corporation;150 Industrial Road;San Carlos, California, 94070